🇺🇸 FDA
Pipeline program

Pegcetacoplan

APL2-203

Phase 2 small_molecule terminated

Quick answer

Pegcetacoplan for Neovascular Age-related Macular Degeneration is a Phase 2 program (small_molecule) at Apellis Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
Apellis Pharmaceuticals
Indication
Neovascular Age-related Macular Degeneration
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials